Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
about
Immune response to vaccine adjuvants during the first year of lifeProlonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.Modulation of adaptive immunity with Toll-like receptorsTargeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.The regulation of Th1 responses by the p38 MAPKImmunization of aged pigs with attenuated pseudorabies virus vaccine combined with CpG oligodeoxynucleotide restores defective Th1 immune responses.TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanismsAdjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.Liposome-nucleic acid immunotherapeutics.TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection.Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease.Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerPDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes.A rational, systematic approach for the development of vaccine formulations.Toll-like receptor and its roles in myocardial ischemic/reperfusion injury.Plasmid vector-linked maturation of natural killer (NK) cells is coupled to antigen-dependent NK cell activation during DNA-based immunization in miceCpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responsesPhosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry.Activation of human and chicken toll-like receptors by Campylobacter spp.Effects of KLK Peptide on Adjuvanticity of Different ODN SequencesChitosan-DNA nanoparticles enhanced the immunogenicity of multivalent DNA vaccination on mice against Trueperella pyogenes infection.Humoral and cellular immune response induced by antigenic protein of Sarcoptes scabiei var. caprae.
P2860
Q27016633-8A9F381C-1416-4E23-B510-84010E0BD2CCQ30374752-CA86A71E-BC56-4351-9BC2-CDB79E6C9546Q34016666-55CEE9B0-4EA7-4C20-95B6-75EC71DD9239Q34048648-D9CA17FE-95AA-460B-9929-0315CE8DA4EBQ34630433-0E15931D-C58E-4BD7-B8FD-ECBE8C94BCEBQ34778728-7AFA4012-C240-4693-88D9-B930EF05321DQ34807008-05A1986A-6B72-4662-82B8-6672FF8C3562Q35895400-8E8A6C1C-DF26-472F-A307-274F7D726F41Q36229051-F0EF714B-78A0-4B47-B77C-5D8AFDABF926Q36517160-8EAF074B-2FE2-4886-9707-BDE6600E0843Q36552864-52B24575-E9EF-4162-A0A0-778789D98273Q36941127-573095F0-7EB1-47D8-BB4D-EE61F16C55DBQ37015889-F881DA25-ABC8-4BB1-B33F-2BFE39691606Q37365673-B864EA8D-A8F7-4AEA-8521-5E18257316C0Q37408390-B2C77DE0-76BE-40B1-B7D2-4E8879DEBBDBQ37846559-F4479B7D-FA9C-4F93-9F08-E8EE409CB7FEQ37860122-C551C335-FED0-4FC6-8951-E27F72C05CA0Q38749284-D2ED65DB-99A3-46D0-92E5-65B3A26815E3Q39657741-51767A2A-91EA-463C-90D9-9D647E2CBB6DQ40027571-271B9678-AE88-40E5-86C2-F764387DAFE0Q42076458-14C1ABC8-773F-4E3F-AC73-B0FCD74D40D1Q42434134-34E7D24D-C2C5-4CEF-A9EE-F4D65C6B967FQ49278291-1A7C9486-C911-4F85-8BAE-A4050D7DE031Q55714474-69CADD7F-3E29-42E6-BC05-560736C6419D
P2860
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@ast
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@en
type
label
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@ast
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@en
prefLabel
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@ast
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@en
P1476
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA.
@en
P2093
M J McCluskie
P304
P577
2006-01-01T00:00:00Z